Zampino M G, Lorizzo K, Rocca A, Locatelli M, Zorzino L, Manzoni S, Mazzetta C, Fazio N, Biffi R, De Braud F
Division of Medical Oncology, European Institute of Milan, 20141 Milan, Italy.
Anticancer Res. 2006 May-Jun;26(3B):2425-8.
A promising regimen including 5-Fluorouracil, methotrexate and oxaliplatin is reported.
Patients with untreated measurable metastatic disease received bolus 5-Fluorouracil (600 mg/m2) on days 2 and 16, modulated by methotrexate (200 mg/m2) 24 h earlier, alternated with 4 weeks of continuous infusion of 5-Fluorouracil (200 mg/m2/daily) plus oxaliplatin (130 mg/m2) on days 29 and 56, followed by 2 weeks of rest. Serum vascular endothelial growth factor (VEGF) was analyzed at baseline and before every cycle.
Fifty-eight patients were enrolled. Objective remissions were reported in 45.6% (95% CI=34.3%, 57.3%). The median progression-free survival was 7.8 months and the median overall survival was 19.4 months. No grade 4 toxicity was reported, except for one case of diarrhea. The serum VEGF evaluated in 23 patients showed a decreasing trend during therapy.
The regimen was active, well tolerated and may be a possible option in patients not suitable for radical surgery.
据报道，一种包含5-氟尿嘧啶、甲氨蝶呤和奥沙利铂的有前景的治疗方案。
未经治疗的可测量转移性疾病患者在第2天和第16天接受大剂量5-氟尿嘧啶（600mg/m²），24小时前用甲氨蝶呤（200mg/m²）进行调节，在第29天和第56天与持续输注4周的5-氟尿嘧啶（200mg/m²/天）加奥沙利铂（130mg/m²）交替进行，随后休息2周。在基线和每个周期前分析血清血管内皮生长因子（VEGF）。
纳入58例患者。报告客观缓解率为45.6%（95%CI = 34.3%，57.3%）。无进展生存期的中位数为7.8个月，总生存期的中位数为19.4个月。除1例腹泻外，未报告4级毒性。对23例患者评估的血清VEGF在治疗期间呈下降趋势。
该方案有效，耐受性良好，可能是不适合根治性手术患者的一种选择。
